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INTRODUCTION
Many human breast cancers have amplified wild-type Neu (Her2) protooncogenes. This genetic change is associated with a poorer prognosis and is likely involved in the progression stage of this disease. It is still not known from either human or rodent models whether amplified wild-type Neu is involved in the etiology of breast cancer. We have begun to develop rat transgenic models to address this question. The first overexpressing line -6500 -expresses high levels of wild-type Neu in both male and female mammary gland. Unexpectedly, only male transgenic rats develop mammary cancer. These cancers develop at a high frequency and distantly metastasize to bone, liver, lung and kidney.
This model has the potential to serve as an excellent male breast cancer model and also to test our central hypothesis that Neu and high androgen levels in postmenopausal women will interact to increase risk to postmenopausal breast cancer. This hypothesis is based on the association of high levels of serum and urinary androgens with increased risk to postmenopausal cancer. (High levels of androgens are associated with lower breast cancer risk in pre-menopausal cancer.) In addition, our data show that male Neu transgenic castrated rats and ovariectomized females do not develop mammary cancer. It is also known that most female breast cancers have androgen receptors.
Under the first aim we will construct additional Neu transgenic rat lines to verify and extend our observations. Aim 2 will endocrinologically manipulate female Neu-transgenic rats in a way that models high androgen postmenopausal women. It will then ask if these rats will now develop female breast cancer. Aim 3 will explore alternative reasons of why these female transgenics do not develop breast cancer by examining levels of Neu co-receptors and their ligands. In addition, the role of genetic background as it relates to female breast cancer development in this model will be explored.
There are two aspects of the relevance of these studies to breast cancer. The first is to provide a relevant model for male breast cancer. This orphan disease is often mistreated and requires additional research resources. The second area of study will explore a novel potential etiologic pathway for post-menopausal cancer. It may ultimately lead to novel chemoprevention strategies and drugs for postmenopausal women with high serum androgen levels.
B. BODY Task la/b -Produce and characterize additional MMTV-Neu rats
We have produced and characterized additional MMTV-Neu transgenic rats, all on the SD genetic background. A total of nine founder rats were produced. One of the female founders was sterile (line 2423), one founder did not show germ-line transmission of the transgene (line 2465) and the other seven lines were expanded for characterization (lines 2477, 2453, 2479, 1447, 1455, 1473, 1477) . Line 2477 had a similar phenotype as line 6500 in terms of overexpression of Neu in the mammary gland and the development of mammary tumors in the male rats at -1 year of age. FISH was used to map the integration site of the neu transgene in lines 6500 and 2477. Line 6500 contained -3-6 copies of the transgene in chromosome 10, while line 2477 had -1-2 transgene copies in chromosome 5. Two other lines, 1447 and 1473, Gould, Michael N. DAMD17-01-1-0459 showed mammary carcinoma development in the male transgenic carriers, but not in the female carriers at 16-21 months of age, a phenotype similar to that observed for lines 6500 and 2477.
Immunohistochemistry (IHC) results confirmed over expression of Neu in the mammary glands of transgenic male and female carriers for both lines 1447 and 1473, although line 1473 tissues did not show as high of levels of Neu expression as the others. Interestingly, lines 1455 and 2479, which did not develop mammary carcinomas in long-term phenotype experiments, showed overexpression of the Neu protein in male and female mammary glands collected at 17 to 30 weeks of age.
Task 1 cid -Produce and characterize NRL-Neu transcqenic rats A NRL-Neu vector was made and used to generate transgenic rats. Five male founders were generated on the SD genetic background (lines 122, 124, 144, 156, 164) and one male founder on the inbred WF genetic background (line 196) . For line 156, there was no germ-line transmission of the transgene. None of the founder male rats developed mammary carcinomas when necropsied at -18-22 months of age. Male and female offspring for all the NRL-Neu transgenic lines failed to develop mammary carcinomas between 9 to 22 months of age.
IHC was done on mammary glands from -17 week old transgenic and non-transgenic carriers of NRL-Neu lines 122, 124, and 144. Line 124 showed overexpression of the Neu protein while lines 122 and 144 did not. It is possible that the lack of tumors in line 124 which over expressed the neu gene product could be due to a specific target cell population which differs from the mammary cell population targeted by the MMTV promoter.
Task 2 -Set up and run experiments to determine the effects of testosterone and DHT on the development of breast cancer in male and female rats This task has been completed. The results are summarized below and can also be found in the Cancer Cell paper included in the Appendix.
a)
The generation of Neu transgenic (TG) rats that over expressed Neu mRNA in a limited number of tissues including the mammary gland (pg. 68 - Fig. I -Appendix).
b)
The TG mammary gland overexpressed Neu at the protein level. The overexpressed protein was membrane associated (pg. 69 - Fig. 2 -Appendix).
c)
Mammary carcinomas developed in untreated male rats. These cancers were androgen dependent (pg. 69-70 and Table 1 -Appendix).
d)
If female rats are supplemented with androgens they also developed mammary carcinomas (pg. 70 and Table I -Appendix).
e)
The Neu TG was amplified in mammary carcinomas as well as in surrounding normal mammary parenchyma but not stroma .
f)
Unlike the mouse Neu-transgenic lines in which almost all cancer contains mutated Neu, no mutations in the amplified Neu transgene were found in these rat carcinomas. This characteristic of activation by amplification and not mutation is also found in human breast cancer (pg. 71-72 -Appendix).
Gould, Michael N. DAMD17-01-1-0459 g) Carcinoma arising in both male and female transgenics expressed both Neu and androgen receptor (AR) (pg. 72 and Fig. 4 ).
h)
Physiological levels of androgens are not needed for Neu transgene expression .
i)
Neu overexpression can maintain the morphology of the male mammary gland in castrated rats (pg. 73-74 and Fig. 6 -Appendix).
j)
Mammary carcinomas in TG rats can become androgen independent (pg. 74 and Fig. 7 -Appendix).
Task 3a -Characterize the phosphorylation status of Neu in male and female trans-genic line 6500 rat mammary gland
We used IHC using a phospho-neu antibody to characterize Neu-induced carcinomas. We found only a few cells to stain positive. We also used Western with the same antibodies with negative results. In conclusion, attempts to address phosphorylation status of Neu were inconclusive. It may be the case that only a minority of cells have phosphorylated Neu or that the antibodies used do not recognize the rat phosphorylated protein.
Task 3blc -Assay the mammary glands of these rats for Neu co-receptor and ligand levels
We evaluated the expression of EGFR, erbB-3 and erbB-4 in the transgenic mammary gland of male and female rats. Results suggest higher expression of EGFR in the male mammary gland compared to the female glands, especially in older animals. ErbB-3 and erbB-4 did not appear to differ in any of the groups. Overall, there seemed to be less erbB-4 compared to EGFR and erbB-3. Given these results there is no scientific reason to supplement our transgenic rats with these receptors since they are all present in the mammary gland of our transgenics.
Task 4a -Produce congenic rats
We have produced hemizygous congenic rats for the MMTV-Neu transgenic line 6500 by moving the transgene from the SD genetic background to the inbred WF strain using successive backcrossing. Currently, we are using N10 generation rats to produce homozygous transgenics. Preliminary data from the N3 generation suggested that the male transgenic carriers will develop mammary carcinomas (n=3/3) but at a longer latency that those on the SD genetic background; however, at the N9 generation, none of the five neu/+ transgenic male congenic carriers developed mammary tumors at 24 months of age. We will continue to evaluate these WF congenics as it is possible the homozygous transgenic/congenic rats may develop mammary tumors.
Task 4b -Evaluate tumoricienesis in these strains
Since the latency of mammary tumor development of line 6500 neu transgenic male carriers on the WF genetic background appears to be increased, we decided to examine several line 6500 MMTV-Neu transgenic F1 strains. Line 6500 transgenic male carriers were bred with WF, LEW, BUFF, NBL and F344-CDF female rats to produce F1 male/female transgenics and non-transgenic littermates to follow long-term for mammary tumor development. Current necropsy results are detailed in a table below. None of the female F1 rats developed neu-induced mammary Gould, Michael N. DAMD17-01-1-0459 carcinomas at any of the time points evaluated. The (LEWxSD)F1 males developed mammary carcinomas more rapidly than the other F1 strains. The (BUFFxSD)F1 and (NBLxSD)F1 males appeared to have the longest latencies for developing mammary tumors and also had fewer mammary carcinomas developing per rat at necropsy. This study is currently on-going with an additional 75 rats still on-study. Necropsies of these rats along with the SD neu/+ transgenic controls will take place prior to 12/04. C.
KEY RESEARCH ACCOMPLISHMENTS
We have produced four independent strains of Neu-transgenic rats that spontaneously develop mammary carcinomas in males. Females supplemented with androgens also develop mammary carcinomas. These carcinomas activated Neu by amplification and not by mutagenesis. We have thus developed a useful model of Neu associated mammary carcinogenesis. This answers a key question of whether the amplification of wild-type Neu is only associated with tumor progression or is it also possibly involved in breast cancer etiology. These data presented provide the first model to clearly demonstrate that the amplification of wild type Neu can induce mammary cancer.
The yield of mammary carcinomas with a neu etiology has been clearly shown to be dependent on genetic backround. This suggests that they are modifier genes that can affect susceptabiliy to neu associated breast cancer. The models and information obtained in this project provides the necessary tools to map and positionally clone these modifiers. Knowledge of such genes might aid in developing prognostic marker for the likelihood of the progression of HER2 overexpresing DCIS to breast carcinomas. In summary:
--We have produced and characterized the first rodent model in which mammary cancer results from the amplification of the wild type gene as it does in women.
---Androgens may play an important role in the etiology of neu associated postmenopausal breast cancer.
--The yield of mammary carcinomas from neu over expression is strongly influence by genetic background. 
E. CONCLUSIONS
The contribution of Neu to the etiology of breast cancer is poorly understood. The novel transgenic rat model that we describe here is a rodent model of the neu proto-oncogene that does not require somatic mutational activation of Neu to induce mammary carcinomas. This finding is pertinent to human breast cancer, where Neu mutations are nonexistent. This report also shows an absolute requirement for androgens in Neu-mediated mammary carcinogenesis. Our results potentially could lead to a greater understanding of the mechanistic pathways that drive mammary carcinogenesis associated with Neu overexpression in both men and postmenopausal women, for whom elevated testosterone is a strong risk factor for the disease. Finally we show the importance of genetic background in the penetrance of neu for a cancer phenotype. This suggests the presence of neu modifier genes, which could both serve as prognostic marker or therapeutic targets once identified and characterized.
F. REFERENCES
See pg. 77-79 of Appendix.
G. APPENDIX
Androgen Introduction against Neu-overexpressing breast cancers (Cobleigh et al., 1999; Slamon et al., 2001; Vogel et al., 2001 ). However, not all Neu (also known as HER-2/ErbB-2) is one of four members in women respond to these treatments, and the precise role that a family of tyrosine kinase growth factor receptors that also Neu plays in the etiology of breast cancer remains poorly underincludes HER-1/EGFR/ErbB-1, HER-3/ErbB-3, and HER-4/ stood. A critical question that remains unknown is whether Neu ErbB-4. Comprehensive in vitro studies in cell lines have estabis involved directly in the initiation of breast cancer or rather lished that these four receptors form a complex array of homodiinstead only helps to drive cancer progression. mers and heterodimers in response to ligand binding, with Neu Several rodent models have been developed to investigate serving as the preferred heterodimer binding partner for the the role of Neu in breast cancer. The first transgenic (TG) mice other three members. In particular, Neu stabilizes ErbB heterodeveloped to study Neu utilized the mouse mammary tumor dimers, leading to enhanced mitogenic signaling (Yarden, 2001) .
virus long terminal repeat (MMTV LTR) to direct expression of These in vitro experiments have solidified the importance of a mutated rat neu oncogene to the mammary gland (Bouchard Neu heterodimer formation in regulation of the ErbB signaling et al., 1989; Muller et al., 1988) . The same mutated neu onconetwork. In contrast, mutant-activated neu oncogenes predomigene also has been delivered to the mammary epithelium of nantly form Neu homodimers (Siegel et al., 1994; Siegel and rats via infusion of recombinant retroviral vectors directly into Muller, 1996; Yarden, 1990) . the mammary duct in situ (Wang et al., 1991a) . The neu oncoThe ErbB family has been associated with many different gene used in these studies contains a single point mutation in the human cancers. The connection between Neu and breast cantransmembrane domain (Bargmann et al., 1986) , which results in cer has received the most attention. Slamon was the first to its constitutive dimerization and activation of the intrinsic tyroshow that neu gene amplification occurred in 25%-30% of sine kinase activity (Bargmann and Weinberg, 1988 ; Weiner human breast cancers and that this correlated with a poor paet al., 1989) . In all of these rodent models, the activated neu tient prognosis (Slamon et al., 1987) . Subsequent studies reoncogene induced multiple mammary carcinomas. However, in vealed that the Neu protein also was overexpressed in the breast human breast cancer, activating mutations of neu have not been carcinomas, correlating with gene amplification (Berger et al.,
found (Lemoine et al., 1990) . The finding that human breast 1988). Numerous clinical studies since then have consistently cancer is associated with overexpression of only the nonmufound the same association between Neu overexpression and tated Neu proto-oncogene led to the development of additional breast cancer. Recently, there have been advances in the devel-TG rodent models. The human neu proto-oncogene under the opment of monoclonal antibody therapies directed specifically control of the MMTV was used to generate both TG mice (Suda " SIGNIFICANCE
The contribution of Neu to the etiology of breast cancer is poorly understood. The novel transgenlc rat model that we describe here Is a rodent model of the neu proto-oncogene that does not require somatic mutational activation of Neu to induce mammary carcinomas. This finding Is pertinent to human breast cancer, where Neu mutations are nonexistent. This report also shows an absolute requirement for androgens In Neu-medlated mammary carcinogenesis. Our results potentially could lead to a greater understanding of the mechanistic pathways that drive mammary carcinogenesis associated with Neu overexpresslon in both men and postmenopausal women, for whom elevated testosterone Is a strong risk factor for the disease.
et al., 1990) and rats (Davies et al., 1998 (Davies et al., 1998) . The rat neu a M TG male 0 5 II TG female proto-oncogene regulated by MMTV also has been used to N rt create TG mice (Guy et al., 1992) . These female TG mice devel--4 oped mammary carcinomas, but the total tumor burden was 3 much reduced and the latency was considerably longer com-C Z pared to mammary carcinogenesis in the activated neu TG mice (Muller et al., 1988) . A subsequent study, however, revealed
• 2 that at least 65% of the mammary carcinomas in the neu proto-1 oncogene TG mice contained somatic deletion mutations within the extracellular region of the neu transgene (Siegel et al., 1994) .
0
The net effect of these mutations was constitutive homodimerYoung Adult Old Adult ization and activation of Neu (Siegel and Muller, 1996) , which B 6 is functionally analogous to the transmembrane point mutation 0] NTG studied in earlier models. Therefore, it remained to be shown hormonal therapy (Wang et al., 1992) . In addition, both rat and , human mammary cancers frequently are hormone dependent, 1 while murine mammary tumors are virtually all hormone indeiriin pendent (Nandi et al., 1995) . In this report, we describe the o generation and characterization of TG rats overexpressing the n I0 a. CL 0. > rat Neu proto-oncogene in the mammary gland and the effects <(< of androgens in mediating mammary carcinogenesis. We generated TG Sprague-Dawley rats using a construct condays) adult NTG or TG rats. Total RNA was isolated and the level of neu taining the rat neu proto-oncogene cDNA under the control mRNA was determined from 4-6 rats/group following normalization to 18S rRNA using quantitative RT-PCR. The data is presented as the mean normalof the MMTV. A real-time RT-PCR assay based on TaqMan ized neu expression for each group plus SD. Data was compared between chemistry was used to quantitatively assess the level of neu NTG and TG rats for each sex and age group, with an asterisk indicating mRNA expression in a variety of tissues from TG rats or their higher expression in TG rats (p < 0.01). B: Testis (T), lung (LU), liver (LI), skeletal nontransgenic (NTG) littermates. After normalization of the neu muscle (MU), and submaxillary salivary gland (SG) were collected from levels to 18S rRNA, the mean neu mRNA expression for each young (78-81 days) adult males. Dorsolateral prostate (DLP), seminal vesicle (SV), and coagulating gland (CG) were collected from old (419-425) adult group was compared between TG and NTG tissues. neu mRNA males. Ventral prostate (VP) was collected from both young (YA) and old levels were determined first in mammary glands from young (OA) adult males. Total RNA was isolated and the level of neu mRNA in (78-82 days) or old (419-431 days) adult male and female rats each tissue was determined following normalization to 18SrRNAusingquan-( Figure 1A ). Both NTG males and females had little neu mRNA titative RT-PCR from 2-3 rats/group (CG) or 3-4 rats/group (all other tissues).
The data is presented as the mean normalized neu expression for each expression in the mammary gland at either age. Compared to group plus SD. Data was compared between NTG and TG rats for each their NTG littermates, young TG males and females demontissue, with an asterisk indicating higher expression in TG rats (p < 0.01). strated 4.9-fold (p = 0.004) and 1.4-fold (p = 0.147) neu mRNA overexpression, respectively, in the mammary gland. This overexpression of neu mRNA was increased in the old TG rats, with males and females expressing 10.9-fold (p = 0.007) and 7.6-fold (p = 0.008) higher levels of neu, respectively, compared to tate (4.7-fold). With aging, neu mRNA expression in the TG age-matched NTG rats. In the old TG mammary gland, neu ventral prostate increased 2.2-fold (p = 0.048). In all other tismRNA was expressed at equivalent levels in the male and female sues, there was no statistical difference in neu mRNA expression (p = 0.219).
between TG and NTG males at a level of significance p < 0.01. We next evaluated whether neu mRNA was overexpressed In addition to evaluating the female mammary gland for neu in any other tissues of the TG male (Figure 1 B) . At a threshold mRNA expression, we also analyzed neu mRNA levels in the of p < 0.01, there was neu mRNA overexpression in TG males ovary of the young female rat. There was no difference in ovarian relative to NTG males in the lung (2.0-fold), dorsolateral prostate neu mRNA expression between TG and NTG females (p -(1.5-fold), young ventral prostate (2.3-fold), and old ventral pros-0.070). (Figure 21 ).
-" -, In contrast to the large overexpression of Neu within the TG S" " "'female mammary gland, the ovary, uterus, and cervix of TG controlling susceptibility to mammary carcinogenesis in the neu TG rat (Table 1) . Young adult TG males and females underwent bilateral gonadectomy. NTG littermates were similarly treated. All of the rats were sacrificed between 421 and 468 days of -The TG rat mammary gland overexpresses Neu protein age, approximately 1 year after gonadectomy. Orchidectomy The mammary glands of TG and NTG rats also were compared completely prevented the development of mammary carcinoutilizing immunohistochemistry with a mouse monoclonal antimas in all of the TG males, while ovariectomy of the TG female body directed against Neu. In both young TG males and females, did not result in mammary cancer. All NTG rats were cancerthere was clear Neu overexpression at the plasma membrane free. To verify that the absence of androgens was responsible for of epithelial cells compared to the NTG (compare Figures 2A the inhibition of carcinogenesis, we reconstituted an androgenic versus 2C and 2B versus 2D). Stromal cells displayed little to environment in gonadectomized TG and NTG males and fe- TG and NTG male and female rats were randomly divided into various treatment groups at 47-57 days of age. Females were kept as virgins or consecutively mated twice as young adults (biparous), Mammary carcinomas were scored as palpable when they reach 3 mm in diameter. Double asterisk indicates palpable tumors could not be accurately assessed due to the formation of numerous milk cysts. Mammary carcinoma data was collected at necropsy. The data is presented as the group mean ± SD. Abbreviations: orch, orchidectomy; ovx, ovariectomy; nd, not determined.
males by long-term treatment with either testosterone MT) or the mammary gland. At days 10-14 of pregnancy, neu mRNA levels nonaromatizable androgen 5a-dihydrotestosterone (DHT). We were elevated by 2.5-fold compared to the young virgin TG did not examine the effects of androgen treatment on mammary female (data not shown). Therefore, we placed young females carcinogenesis in intact female rats, because androgens induce through two consecutive full-term pregnancies and then sacrinumerous changes to the rat ovary, including atrophy, cyst ficed them approximately 235 days after the second pregnancy formation, and arrest of estrous (Burrows, 1949) . These effects when they were an average of 439 days of age (Table 1) . Despite would confound interpretation of the results. The rats were mainhaving a 4.5-fold higher level of neu mRNA expression comtained continuously on androgens until sacrifice at 390-471 pared to the intact TG male, TG biparous females remained days of age. While androgen treatment did not induce mammary cancer-free. The effect of additional pregnancies beyond two tumors in any of the NTG rats, multiple mammary carcinomas on mammary carcinogenesis was not investigated, due to our did develop in almost all of the TG rats. The incidence of carcinoexperience that lactating Sprague-Dawley rats are susceptible mas among the males was 100%, irrespective of which androto developing ulcerating milk-filled lesions, which necessitates gen was used. For the females, 75% and 80% of those treated sacrifice. These lesions are more likely to occur with increasing with T and DHT, respectively, developed mammary carcinomas, number of pregnancies. However, it should be pointed out that Radioimmunoassays of serum androgen levels at necropsy from an additional cohort of biparous TG females (n = 4) were oba subset of the rats showed that T implants resulted in a 2-to served for approximately 13 months after the first pregnancy. 3-fold elevation of T and a 2-to 4-fold elevation of DHT comTherefore, this cohort experienced elevated neu expression levpared to the untreated male. DHT implants resulted in 12-fold els for a period of time equivalent to 13-month-old TG males, elevated DHT levels, while T was undetectable (<0.1 ng/ml, in whom the mammary cancer incidence was approximately data not shown). Androgen-treated gonadectomized male and 86% with numerous, large carcinomas in multiple glands. When female rats had serum estradiol levels equal to that of the unthis group of biparous TG females was sacrificed at 558 days treated male, and there were no appreciable differences in seof age, there was only a single small mammary carcinoma in a rum levels of T or DHT among similarly treated males and fesingle rat. However, spontaneous mammary cancers can be males (data not shown).
observed in normal female rats of advanced age. Finally, we asked whether mammary carcinogenesis in the TG female could be driven without androgen supplementation
The neu transgene is amplified in mammary if neu expression was elevated to levels above that normally carcinomas found in the untreated TG female. We were able to show that Fluorescence in situ hybridization (FISH) was used to map the pregnancy stimulated neu mRNA expression in the TG female transgene in lines 6500 and 2477. Metaphase chromosomal complete transgene as a probe. A single strong signal was detected in 25%-40% of mammary carcinoma nuclei ( Figures  3C and 3D ). In comparison, normal mammary epithelium surrounding the carcinoma displayed only a weak FISH signal in 20%-30% of the nuclei ( Figure 3E , arrows). Hybridization with the probe did not occur in mammary stromal fibroblasts and vascular cells within the same sections. Also, testis from the same cohort of TG males did not have detectable FISH signals ( Figure 3F ). The endogenous neu gene was not detected in interphase chromosomes, unlike in the lymphocyte metaphase chromosomal preparation.
Mammary carcinogenesis is not associated with somatic mutational activation of the neu proto-oncogene in the neu TG rat To assess if the mammary carcinomas arose due to somatic mutational activation of the neu proto-oncogene as was found in the neu TG mouse, the entire coding region of the neu transgene was sequenced from five carcinomas from five individual untreated TG males. Similarly, the complete neu transgene was sequenced from three mammary carcinomas arising in orchidectomized plus DHT-treated TG males and three carcinomas from ovariectomized plus DHT-treated TG females. These carcinomas from DHT-treated rats were selected from three different individual males and females. All of the mammary carcinomas analyzed were completely free of mutations within the entire neu coding region, regardless of sex or hormonal treatment. Because the neu transgene was amplified in the carcinomas, rare neu copies with mutations might remain undetected by sequencing the pooled PCR-amplified transgene. To address this, we therefore performed an extensive clonal sequence analysis of an approximately 750 bp region of the neu transgene The endogenous neu gene is shown on the telomeric end of chromosome region was POR amplified using DNA from the same six 10 (small arrow) (Koelsch, 19981 . while the transgene of line 6500 was intemammary carcinomas arising in DHT-treated gonadectomized grated into the centromeric region of chromosome 10 (large arrow). DAPI TG males and females (three from each sex) that were combanding patterns are shown from the same metaphase preparation (B).
pletely sequenced earlier. Because random mutations induced
Interphase FISH was conducted on paraffin-embedded tissue sections from by DNA polymerase were expected, we set criteria that a mutamammary carcinomas (C and D), adjacent normal mammary epithelium (E), and testis (F) of TG males. The transgene signal was amplified in carcition would only be considered "relevant" if it appeared in two noma compared to normal gland (E, arrows). No signal was detected in separate PCR reactions from the same carcinoma. Consetestis.
quently, for each carcinoma, two independent PCR reactions were used, and the resulting PCR products were cloned. A total of 54-66 individual clones from each PCR reaction (108-114 clones per carcinoma) was sequenced throughout the 750 bp preparations from spleen lymphocytes of heterozygous TG neu fragment. A total of 465,038 bases was sequenced from 660 males at approximately 1 year of age were hybridized with a clones. There was a total of 125 mutated bases, representing probe containing the entire transgene. The probe was able to 0.0269% of the total sequenced. This extremely small error rate detect the endogenous neu gene on the telomeric region of is well within the expected error rate due to misincorporations chromosome 10 ( Figure 3A , small arrow). The signal intensity by DNA polymerase during PCR. No clones contained the preof the endogenous neu gene was used to estimate the copy viously described activating point mutations within the transnumber of the neu transgene. Line 6500 contained 3-6 copies membrane and adjacent extracellular domains that are associof the transgene on chromosome 10q12 ( Figure 3A , large arrow), ated with mammary carcinomas in the neu TG mice models. while line 2477 had 1-2 transgene copies on the telomeric region Of the mutations that were found, only one (a C -T change of chromosome 5 (data not shown). DAPI banding patterns of nucleotide 2137) was present in clones derived from both identified the specific rat chromosomes containing positive inte-PCR reactions of the same tumor. However, this mutation did grated FISH signals ( Figure 3B) . not result in a change of the encoding amino acid. We next determined if mammary carcinomas in heterozyWe next investigated whether the somatic neu mutants gous TG males displayed amplification of the neu transgene.
found in the TG mouse were capable of inducing mammary Interphase FISH was performed on two paraffin-embedded carcancer in the rat if introduced into the gland exogenously. This cinomas from two untreated 14-month-old males using the experiment was conducted to address the possibility that neu mutations might be arising spontaneously in the untreated fe-A male gland but not leading to the formation of mammary carcinomas. Therefore, we subcloned the activated neu oncogenes Al 8142 and 8567 into a retroviral expression vector and introduced U retrovirus directly into the mammary gland ducts of 13-14 NTG female rats. We could not test these retroviral constructs in the male rat mammary gland, as the lack of nipples in the male rat precludes ductal infusion. neu 8142 and 8567 are examples of somatic constitutively active neu mutants containing deletions4tI in the extracellular domain that are responsible for mammary carcinogenesis in the neu proto-oncogene TG mice (Siegel et al., 1994) . These deletion mutants were compared against the previously characterized neu T, which contains a single activating point mutation in the transmembrane domain (Wang et al., 1991 a) . As with neu T, both neu 8142 and neu 8567 served as powerful oncogenes in the rat, rapidly transforming nearly all of the infused mammary glands in 100% of the animals.
::
TG mammary carcinomas express Neu and AR Mammary carcinomas from TG males and females were compared histologically. All mammary carcinomas, irrespective of .-sex or androgen treatment, had a uniform morphology conah sisting of compact epithelium with a minimal amount of intratumoral stroma ( Figures 4A and 4B) (n = 6) and normal mammary gland (n = 4) revealed 12.6-fold,, : ing ( Figure 4G ). The status of AR also was assessed in carcinothat was untreated (A, C, F, G) or arch + DHT (H), untreated TG male of mas from both males and females treated with DHT. In both line 2477 (D), and TG female of line 6500 that was ovx + DHT (B, E, I). The barin A is 100 pRm and the same scale was used for all panels. Abbreviations:
sexes, there was strong AR expression within the epithelial cells orch, orchidectomy: ovx, ovariectomy. of the carcinomas (Figures 4H and 41) . Collectively, the mammary carcinomas in the neu transgenic rat expressed levels of AR close to that seen in the rat ventral prostate ( Figure 4J ). serum levels of T were undetectable in both long-term gonadecPhysiological levels of androgens are not necessary tomized TG males and females (<0.1 ng/ml, data not shown). for neu transgene expression Despite the absence of T, mammary gland expression of neu We next addressed whether an intact hormonal environment mRNA in gonadectomized TG males and females was not statiswas necessary for expression of the neu transgene regulated tically different from that of the intact, untreated TG male. This by the MMTV. This was done to determine if the absence of suggests that other factors, such as glucocorticoids, are suffimammary carcinomas in the gonadectomized TG rats was due cient to maintain high neu expression levels in the absence of to loss of neu expression. Real-time RT-PCR was used to quanandrogens. In contrast to neu mRNA levels being unaffected by tify the level of neu mRNA from mammary glands of old intact gonadectomy alone, gonadectomized TG rats given exogenous and long-term gonadectomized rats. The mean neu mRNA ex-DHT demonstrated increased neu mRNA expression in the pression from each group was plotted against the mean number mammary gland. Compared to their intact, untreated TG conof mammary glands with carcinomas ( Figure 5 ). As expected, trols, DHT-treated males had 2.7-fold (p = 0.021) and DHT- Mean Normalized neu Expression Figure 5 . Physiological levels of androgens are not necessary for neu transgene expression Mammary glands were collected from old (419-468 days) TG rats. Females were kept as virgins or consecutively mated twice as young adults (biparous), after which they remained untreated until the termination of the experiment. Rats were kept intact or underwent bilateral gonadectomy I year prior to necropsy. Total RNA was isolated and the level of neu mRNA was determined from 4-6 rats/group following normalization to 18S rRNA using quantitative RT-PCR. The mean neu mRNA expression per group isH plotted against the mean number of mammary glands with carcinomas at , the time of necropsy. Horizontal and vertical error bars represent SD for the mean neu mRNA expression and the mean number of mammary glands with carcinomas, respectively. Note that female (intact), female (ovx), and male (orch) are all actually at the zero point for the y axis. They are shown 0 separated for clarity purposes only. Abbreviations: arch, orchidectomy; ovx, ' ovariectomy. treated females had 3.6-fold (p = 0.035) higher neu mRNA expression.
We also determined levels of neu mRNA in the biparous TG female mammary gland approximately 235 days after the cessation of pregnancy. Compared to the intact, untreated TG male, neu mRNA expression in the biparous TG female was 4.5-fold higher (p = 0.033). This elevated level of neu mRNA
K L
expression was similar to that of the DHT-treated female, yet cancer did not arise in these biparous females. Overall, there E £ was no correlation between elevated levels of neu mRNA in the various treatment groups and mammary carcinogenesis. Mammary gland morphology did not differ between intact TG (H). and TG ovx (for 1 year) female (I, K). The bar in A is 100 ýrm and the and NTG rats. Orchidectomy of young male rats resulted in some scale was used for all panels. Abbreviations: orch, orchidectomy: ovx, dramatic morphological changes to the mammary gland in both ovariectomy. TG and NTG males ( Figure 6C ). The mammary epithelial content was markedly reduced. This was accompanied by a loss of central epithelium from the alveoli and the development of a tution of the androgenic environment with DHT completely relumen. These morphological changes were established by 1 stored the mammary gland morphology to that of the intact month after orchidectomy. These changes in the mammary epimale ( Figure 6D ). Furthermore, females maintained on DHT also thelium were proven to be due to androgen ablation, as reconstigained a mammary morphology similar to that of the intact male been restored to that of the intact male ( Figure 6G ). Morphological changes also were apparent in TG females. One year afterD ovariectomy, the NTG female gland consisted largely of atrophied epithelium ( Figure 6H ). However, 63% (5/8) of the ovariectomized TG females displayed partial conversion of the mammary epithelium to that of an intact male (Figure 61 ). In order to determine if these changes to the mammary epithelium were due to Neu overexpression, we performed immunohistochemis-A " try on mammary gland sections from the long-term gonadectomized rats. While the atrophic epithelium of the NTG rats was negative for Neu expression (data not shown), the intact malelike mammary epithelium of the gonadectomized TG males (Figure 6J ) and females ( Figure 6K ) expressed abundant Neu. We then evaluated Neu expression in the young TG males and females 1 month after gonadectomy ( Figure 6L and data not shown). Although the epithelium was atrophied at this early point after gonadectomy, in both sexes there was a small subpopulation of epithelial cells overexpressing Neu. The stimula- as all of the gonadectomnized mammary glands were negative mm in diameter underwent bilateral arch (at age indicated by the arrow) and were regularly palpated for mammary carcinomas !3 mm in diameter for AR expression (data not shown).
D

Neu overexpression substitutes for androgens in the
until necropsy at 602 days of age (n ý 8). The percentage of rats bearing at least one carcinoma at each palpation time point was plotted against Mammary carcinomas in the neu TG rat acquire the the age of the rats in days. B: Total RNA was isolated from mammary carcinoability to grow in an androgen-depleted environment mas of old TG males and the level of neu mRNA was determined after normalization to 18S rRNA by quantitative RT-PCR. Carcinomas were colTwo additional questions of interest were whether established lected from males that were untreated (intact), or arch far either 10 days mammary carcinomas would display a strict androgen depen-(arch, 10 dy) or 6 months (arch, 6 mo). Five to six carcinomas from each dence for growth and whether Neu overexpression could progroup were analyzed. The data is presented as the mean neu mRNA expresmote the emergence of mammary cancer in an androgension for each group + SD. C-F: Mammary carcinoma sections from TG males depleted environment. To address these issues, untreated TG were stained with mouse monoclonal anti-Neu (C and E), H&E (D), or rabbit polyclonal anti-AR (F). Representative results are shown from at least 3-4 males with established mammary carcinomas underwent orchirats/group for arch, 10 dy (C) or arch, 6 mo (D-F). The bar in C is 100 tim and dectomy at 423-430 days of age. The rats were monitored by the same scale was used for all panels. Abbreviation: arch, orchidectomy. palpation to ascertain the effects of orchidectomy on tumor maintenance ( Figure 7A ). Complete regression was defined as the point at which there were no palpable tumors. By 69 days after orchidectomy, 75% of the rats had undergone complete carcinomas. We further extended these findings by using immuregression with a mean time of 46 days. However, after a period nohistochemistry to stain carcinomas for Neu expression 10 of time averaging 96 days without palpable lesions, tumors days ( Figure 7C ) or 6 months ( Figure 7E ) after orchidectomy. began to reemerge. By the time the rats were 598-605 days of These experiments confirmed that the carcinomas continued age, which was approximately 6 months after orchidectomy, to express high levels of Neu in an androgen-depleted hormonal the mammary carcinoma incidence was 88%, involving an averenvironment. We also assessed the AR status of the carcinomas age of 1.4 mammary glands/rat. present 6 months after orchidectomy and all were found to To verify that tumor regression was not simply a consebe negative ( Figure 7F ). The histological morphology of these quence of loss of neu, we performed real-time RT-PCR to meacarcinomas did not differ from those present in intact, untreated sure the level of neu mRNA in carcinomas from an additional males ( Figure 7D ). cohort of rats 10 days following orchidectomy. By this time, serum testosterone levels were undetectable (<0.1 ng/ml, data Discussion not shown), and many of the tumors were actively regressing. The level of neu mRNA in these carcinomas was compared
In this report, we describe a TG rodent model in which mammary with those present 6 months after orchidectomy as well as cancer arises due to overexpression of the nonmutated Neu carcinomas in intact, untreated males ( Figure 7B ). Orchidectomy proto-oncogene. This contrasts with an earlier TG rat model of had no significant effect on neu mRNA expression within the the human neu proto-oncogene described by Davies et al., in which almost no mammary cancers arise in TG females. In a real-time RT-PCR assay to quantify the levels of neu mRNA addition, virgin female TG rats described by Davies et al. had in the male and female mammary glands under various hormonal no transgene expression in the mammary gland (Davies et al., states. This analysis revealed that intact TG males and females 1999). This is a key difference with ourneu TG females described expressed equivalent amounts of neu mRNA at 419-434 days here, which display high Neu overexpression within the virgin of age, a time when nearly 100% of the males had multiple mammary gland. Davies et al. did not evaluate the mammary mammary carcinomas. Furthermore, neu mRNA expression was glands of male TG rats, so it is not possible to compare our maintained at the same level as the intact male in long-term findings in neu TG males with those of theirs. However, the gonadectomized rats of both sexes. In addition, the biparous absence of mammary cancers in the rats described by Davies female displayed a level of neu mRNA expression 4.5-fold higher et al. could likely be explained by their very low neu expression than even the intact TG male. These important findings led to in the mammary gland. In agreement with this hypothesis, we two conclusions. First, neu levels per se do not determine the have not observed mammary cancers in male or female TG rats susceptibility of the mammary gland to carcinogenesis. Secfrom several neu proto-oncogene TG lines that display very low ondly, physiological levels of androgens are not needed to mainto nondetectable levels of neu in the mammary gland. These tain expression of the neu transgene. An implication from these observations imply that there might be a threshold level of neu experiments is that androgens serve a necessary function for overexpression required to induce mammary cancer.
Neu-mediated mammary carcinogenesis apart from transcripWe thoroughly searched for mutations within the neu transtional regulation of the MMTV LTR. gene from mammary carcinomas from both untreated TG males Consistent with this hypothesis, all of the mammary carcinoand rats of both sexes treated with DHT. Sequencing of the mas analyzed from males and females were AR positive but entire neu coding region from 11 carcinomas failed to find any were negative for both ER and PR. This makes it unlikely that mutations in pooled PCR products. Because we found the neu either ER or PR is making a major contribution to mammary transgene to be moderately amplified in mammary carcinomas, carcinogenesis in the neu TG rat. This is consistent with human we also analyzed 660 individual clones containing a fragment breast cancers, for which there is an inverse correlation between of neu cloned from both TG male and female mammary carcino-ER, PR, and Neu overexpression (Berns et al., 1992; Ito et al., mas for mutations. This region of neu almost always contains 1995; Quenel et al., 1995; Zeillinger et al., 1989) . Indeed, in oncogenic mutations in mammary carcinomas from the neu breast cancer cell lines, ER and Neu downregulate each other proto-oncogene TG mouse (Siegel et al., 1994; Siegel and (Pietras et al., 1995; Read et al., 1990 ). These observations have Muller, 1996) . Despite our extensive searching, we did not find led to the general idea that Neu is preferentially associated with any significant mutations.
hormone-independent breast cancers. However, the potential In addition, we considered the possibility that activating role of AR in breast carcinogenesis has received little attention mutations might be arising in female rats but not leading to compared to ER and PR. This is despite the fact that AR expresmammary cancer. Therefore, activating neu deletion mutants sion has been demonstrated in 31%-85% of breast cancers (Siegel et al., 1994) were introduced into the female rat mamusing a variety of methodologies (Allegra et al., 1979; Hall et mary gland via retroviral infusion to ask whether these neu mual., 1998; Isola, 1993; Lea et al., 1989; Miller et al., 1985) . Few tants could serve as oncogenes in the rat. Mammary cancer reports have evaluated associations between Neu and AR in was readily induced in 100% of the infused females, confirming breast cancer (Isola, 1993; Kollara et al., 2001 ; Zeillinger et the potent oncogenicity of these Neu mutants in the rat mamal., 1989) . None of these studies found a positive correlation mary gland. Therefore, since no mammary cancer spontanebetween the two proteins. It is, however, difficult to draw firm ously develops in the untreated neu proto-oncogene TG female conclusion from these reports as all consisted of relatively small rat, we infer that these somatic activating deletion mutations sample sizes. are not arising. Hence, our model shares an important attribute Nevertheless, we present evidence here that, in the neu TG with human breast cancers, which are not associated with mutarat, there are interactions between the AR and Neu signaling tional activation of the neu proto-oncogene (Lemoine et al., pathways that regulate growth of both the normal and cancerous 1990).
gland. In the normal, NTG rat, the male mammary gland was Although we used the same transgene construct to create found to be strictly dependent on physiological levels of androour TG rats as that utilized by Muller and colleagues for producgens to maintain its normal morphology. In addition, the normal tion of neu TG mice, we nevertheless observed striking phenofemale rat mammary epithelium underwent morphological trantypic differences from the mouse model. In the neu TG rat, sition to that of a male rat in response to long-term androgen mammary carcinogenesis was androgen dependent and arose treatment. These observations underscore the critical role that spontaneously only in the male. Significantly, carcinogenesis androgens serve in the normal rat mammary gland. An intriguing could be induced in ovariectomized TG females, but only if they finding was that Neu overexpression in the TG male rat was able were treated with androgens. This is in complete contrast to to rescue mammary morphology after long-term orchidectomy. the neu TG mice, in which mammary carcinomas develop only This restoration occurred despite almost complete androgen in females and males have no lesions (Guy et al., 1992) . The ablation. Even more surprising was the female-to-male morphomale rat mammary cancer phenotype has been demonstrated logical conversion in the mammary glands of ovariectomized in two independent TG lines (6500 and 2477), and in both lines TG females. Neu overexpression was not able to prevent initial these cancers displayed expression of Neu and AR. Therefore, gonadectomy-induced mammary gland atrophy in the transthe novel phenotype that we describe here is not likely to be genic rats. However, the clear presence of a subpopulation of simply a byproduct of a unique integration site for the transgene.
epithelial cells overexpressing Neu in the young, gonadectoTo exclude the possibility of sex differences in transgene mized TG gland strongly suggests that these cells were imparted expression accounting for the male-specific cancers, we used with a selective growth advantage, allowing for eventual mor-phological restoration with a minimal level of androgens. The observation that ovariectomized TG female rats treated with cancerous mammary epithelium also benefited from Neu overandrogens developed mammary cancer at high incidence expression in an androgen-depleted environment. Although means that this model could also help to clarify the role of most of the mammary carcinomas were initially androgen detestosterone in postmenopausal female breast cancer. Several pendent and regressed in response to orchidectomy, mammary prospective clinical studies have shown that an elevated level cancers eventually reemerged several months after androgen of testosterone is a major risk factor for breast cancer in postdeprivation, menopausal women (Berrino et al., 1996; Cauley et al., 1999 ; In both the normal gland and the mammary cancers after Dorgan et al., 1996; Thomas et al., 1997) . Additionally, treatment long-term gonadectomy, there was no detectable expression of both male (Liao et al., 1998) and female (Xie et al., 1999) of AR. Given the requirement for androgens in maintenance of Noble rats with a combined regimen of testosterone and estrothe epithelium following gonadectomy, these results suggest gen induced a high incidence of mammary cancer. Our model, that these growth-stimulatory effects of Neu are mediated in therefore, provides an additional tool to study the role of andropart through the AR pathway in a process that is independent gens in breast cancer with the further advantage that coincident of the receptor itself. As residual amounts of androgens remain estrogen treatment is not necessary for mammary carcinogeneven after long-term orchidectomy, it is not possible to deteresis. mine from our data whether these are truly androgen-indepenIn summary, the work that we present here could lead to a dent mammary epithelial cells or rather are hypersensitive to greater understanding of the role of androgens in mediating the low levels of androgens that remain. However, the fact that breast cancers in both men and women. In particular, it suggests all of these mammary glands were negative for AR would sugthe need to extend these findings to a study of breast cancer gest the former, although more sensitive protein assays would patients. It will be important in this study to examine the correlabe needed to completely rule out the presence of AR.
tion of serum androgen levels with the overexpression of Neu Our report shows interplay between the Neu and AR signalin postmenopausal women with breast cancer. ing pathways within the mammary gland. Recently, it was reported that Neu and AR crosstalk in the prostate. AndrogenExperimental procedures independent xenografts spontaneously developed elevated Neu Generation of TG rats (Craft et al., 1999) . In addition, forced overexpression of Neu
Linearized plasmid encoding the rat neu proto-oncogene under the MMTV in the androgen-dependent prostate cancer cell line LNCaP (pMMTVneuN) (Guy et al., 1992) was microinjected into the pronuclei of resulted in the acquisition of androgen-independent transactiva- Kramarski et al., 1996) . Another group subsequently indicated overexpressed Neu in the male and female mammary gland, with developAkt was also critical for Neu-AR crosstalk (Wen et al., 2000) . ment of male mammary cancer. Line 6500 was further characterized. All Several clinical studies have corroborated the earlier in vitro experiments are from line 6500 unless otherwise specified. TG rats used in experiments. The percentage of prostate cancers overexpressall experiments were heterozygous for the transgene. Screening for the ing Neu increased with clinical progression to androgen indetransgene was performed by PCR using primers directed against the SV40 pendence (Osman et al., 2001; Shi et al., 2001; Signoretti et al., region of the transgene or neu. These primers did not amplify endogenous neu. SV40 primers were 5'-ACTCCACACAGGCATAGAGTGTCTGC-3' and 2000). One report, however, failed to find such a relationship 5'-AGGACACAGAGGAGCTTCCTGGGGAT-3'. neu primers were 5'-CGG (Reese et al., 2001) . Overall, the evidence to date strongly sup-AACCCACATCAGGCC-3' and 5'-TT-TCCTGCAGCAGCCTACGC-3'. ports the hypothesis that Neu is a key mediator in the evolution of androgen-independent prostate cancer. With the addition of Animal surgeries and hormone treatment our findings here, we extend those observations first established ing Neu-mediated mammary carcinogenesis, the TG rats that we describe here could have more general applications in furReal-time RT-PCR thering the understanding of breast cancer. It may be a useful
Frozen tissues were homogenized with a Polytron and total RNA was isolated model for male breast cancer, for which there are no well- , 1997) . The neu primers were used at a final concentration of 500 nM, while the neu probe was used at 125 nM. Each 18S rRNA primer was used at 50 nM and Approximately 750 bp of the neu insert was sequenced from multiple individthe 18S rRNA probe was at 200 nM. A cDNA standard curve was prepared ual clones using the primer 5'-CTTTGGATCGGAGGCTGAT-3'. from rat kidney total RNA (Ambion). The relative level of neu mRNA expression was determined after normalization to 18S rRNA.
Ductal infusion of retroviral neu mutant vectors neu 8142 and neu 8567 from pJ411neu8142 and pJ411neu8567 (Siegel et Histology and immunohistochemistry al., 1994) were subcloned into the retroviral expression vector pJR (Wang Tissues were fixed in 10% neutral buffered formalin and routinely processed et al., 1991 b). The construct JR/neu T was generated previously and reported for histological analysis. After deparaffinization and rehydration, antigen unas JR/neu (Wang et al., 1991 a) . The preparation of concentrated retroviral masking was done by microwaving in Antigen Unmasking Solution (Vector stocks and ductal infusion into the rat mammary gland has been described Laboratories, Burlingame, CA) for Neu, ER, and PR or 5 mM EDTA for AR.
in detail (Thompson and Gould, 2000) . All retroviral neu constructs were Endogenous peroxidases were quenched by soaking the sections in 3%
infused at a titer of 1 x 101 CFU/ml. H 2 0 2 , followed by blocking in 10% horse or goat serum. Primary antibodies and final concentrations used were mouse anti-Neu (Ab-17, NeoMarkers, Statistics Fremont, CA) at 0.5 p•g/ml, mouse anti-ER (Ab-14, NeoMarkers) at 1:200,
The level of neu gene expression was modeled using analysis of variance. mouse anti-PR (Ab-10, NeoMarkers) at 5 pig/ml, and rabbit anti-AR (N-20, Factorial models were fit to various subsets of the data. Likelihood ratio Santa Cruz Biotechnology, Santa Cruz, CA) at 1 p.g/ml. Positive control tests were used to eliminate predictor variables that did not significantly sections for ER were human breast carcinoma (NeoMarkers) and rat uterus improve the fit of the models. For significant main effects and interactions and for PR were rat mammary carcinoma (NeoMarkers) and rat uterus. As with more than two levels, tests were conducted to assess pairwise differa negative control, normal mouse or rabbit IgG was substituted for the ences. The response was transformed to the log scale before analysis to primary antibody at an equal concentration for all experimental samples obtain approximately normally distributed residuals. (Santa Cruz). Secondary antibodies and ABC Reagent were from the Vectastain Elite ABC-Peroxidase Kit and used according to the manufacturer's
